Tumour vascular-disrupting agents in soft-tissue sarcoma
Mené sur 355 patients atteints d'un sarcome des tissus mous de stade avancé, cet essai randomisé international de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout d'ombrabuline au cisplatine en traitement de deuxième ligne
Tumour vascular-disrupting agents are a novel class of anti-tumour drugs that has been extensively studied. Distinct from anti-angiogenic drugs, which are inherently cytostatic and inhibit tumour neovascularisation, tumour vascular-disrupting agents target established tumour vasculature and might be more effective against large tumour masses. Combretastatins are one of the main classes of these drugs in clinical trial development. They are tubulin depolymerising drugs that selectively disrupt the tumour endothelial cytoskeleton and cause rapid tumour vascular shutdown and necrosis.
The Lancet Oncology , commentaire, 2014